Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02015026 · ClinicalTrials.gov registry record
Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 67
- Enrollment target
NCT02015026: Completed study, sponsored by National Cancer Institute (NCI).
NCT02015026 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02015026 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
Background: * Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 months. * The treatment of choice for a localized primary or recurrent tumor is surgical resection. Patients with recurrent or metastatic disease are infrequently curable by surgery alone. * As with most solid tumors, chemotherapy options have limited benefit, although platinumbased therapies have response rates of 25 to 30%. To date no targeted therapy has been shown to be of any value in this disease. * The natural history of ACC can vary greatly with some patients surviving only months while others can live with disease for years. The basis for these differing clinical presentations is not known. While one cannot exclude an immune or other host component as responsible for the diverse clinical courses, it is also possible that there may be a genetic basis for this phenomenon. A bio-specimen repository will be a major step towards more comprehensive studies of this very rare and unusual tumor, and allow us to begin to characterize subgroups within the disease. * Patients with rare tumors seek expert advice in the management of their care. Dr. Fojo has such expertise and is frequently asked to consult in the care of ACC patients throughout the world. A natural history study would establish a more formal mechanism for such referrals, while allowing the systematic collection of epidemiologic data as well as much needed tumor samples. Objective: -To characterize the natural history of adrenocortical cancer, and in the process, collect blood, and tissue samples to study genetic/biochemical pathways involved in the development and progression of adrenocortical cancer (ACC). Eligibility: * Patients greater than or equal to 12 years of age with biopsy-proven ACC * Patients greater than or equal to 12 years of ag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2013-12-13 |
| Est. Completion | 2018-03-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02015026
The ClinicalTrials.gov registry entry for NCT02015026 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02015026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02015026 about?
NCT02015026 is a clinical study titled "Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma". Background: * Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 months. * The treatment of choice for a l...
What is the current status of trial NCT02015026?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2013-12-13. Estimated completion is 2018-03-02.
Who is sponsoring clinical trial NCT02015026?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.